---
title: "Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks. Clinical evidence covers RAPIDe-3, RAPIDe-1, RAPIDe-2, and PHA121-C001. 782 evidence topics quoted from 209 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Deucrictibant

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Hereditary angioedema

<a id="topic-1.1.1-1"></a>

##### Summary: definition and epidemiology

Hereditary angioedema (HAE) comprises a group of genetic disorders characterized by recurrent episodes of angioedema, typically mediated by bradykinin. It is most commonly caused by a deficiency of C1 inhibitor (C1-INH) and is subclassified into type 1 (quantitative deficiency) and type 2 (dysfunctional protein); a further form, HAE with normal C1-INH, occurs in patients with normal C1-INH function. HAE with C1-INH deficiency is autosomal dominant, about 5% of mutation carriers remain asymptomatic over their lifetime, and up to 25% of cases result from de novo mutations. In one cohort of 239 individuals, 90.4% had type 1 and 9.6% had type 2.

HAE is estimated to affect 1 in 50,000 people worldwide. One pooled analysis reported a diagnosed annual prevalence of 1.70 per 100,000 (95% confidence interval [CI], 1.58 to 1.83) for combined types, with pooled regional estimates of 1.43 per 100,000 in North America and 1.64 per 100,000 in Europe; a pooled analysis of 24 studies reported 1.22 cases per 100,000 (95% CI, 0.91 to 1.53). For all types of HAE in the United States, a claims-based algorithm yielded unadjusted prevalence estimates of 2.67, 2.61, and 2.43 per 100,000 for 2018, 2019, and 2020, corresponding to 9559, 9341, and 8694 people diagnosed with HAE; the corresponding estimates based on expert physician analysis were 2.13 (7602 people), 2.03 (7275), and 1.84 (6595). The sponsor's annual report states, citing HAE International as of October 2014, that HAE affected 1:30,000 to 1:80,000 individuals globally, or at least 7,000 patients in the US and at least 15,000 patients in the EU. The mean annual incidence of diagnosed HAE types 1 and 2 in Finland was 0.16 per 100,000, and a second analysis reported an incidence of 0.36 per 100,000 in 2024, measured as patients newly treated for HAE.

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/); [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/); [Craig et al. (2026b)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema); [Fisch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39827848/); [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086); [Danielsson et al. (2025)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2025/poster-session-2-2/current-use-of-hereditary-angioedema-hae-treatments-in-sweden-an-analysis-of-the-national-prescribed-drug-register)

<a id="topic-1.1.1-2"></a>

##### Summary: natural history, attack characteristics, and mortality

Symptoms typically begin in childhood and worsen during puberty. In one cohort, symptoms began at a mean age of 11.2 years (SD 7.7), and only 370 (6.5%) of the following cumulative 5736 years were symptom-free. Untreated patients may experience attacks every 7 to 14 days on average; swelling worsens over the first 24 hours and subsides over the next 48 to 72 hours, usually lasting no more than 5 to 7 days. Abdominal involvement occurs in 70% to 90% of individuals, and laryngeal involvement, which accounts for less than 1% of all attacks, occurs at least once in about half of patients. Among 123 patients in another cohort, 61 (49.6%) experienced laryngeal edema, and the mean interval between onset and maximum development of laryngeal edema was 8.3 hours. At a Milan center, 227 patients reported 4244 attacks, of which 35% were not treated; median attack duration was 10 h with approved therapies and 45 h without treatment. A review of 65 articles reported mean or median delays from symptom onset to confirmed diagnosis of 3.9 to 26 years, and a guideline describes a decline in diagnostic delay from an average of 21 years in the 1970s to around 7 to 10 years currently.

In one cohort, 70 of 214 patients who had died asphyxiated during a laryngeal attack, 63 of them with undiagnosed HAE. Among 75 fatal events in another cohort, asphyxiation owing to laryngeal edema was the cause of death in 39 (52%); the diagnosis of HAE was made after death in 65 of the 75, the median time from symptom onset to death was 8 hours, and the life span of patients who died of laryngeal edema was reduced by 20 years compared with those who died of other causes. An analysis of studies including 3292 patients reported 411 deaths from asphyxia due to laryngeal edema, an average of one death for every 20 patients, and a guideline estimates the risk of death with laryngeal edema at 20% to 25% in the absence of a diagnosis. In another study, 36.9% of participants with HAE due to C1-INH deficiency and 15.4% of those with normal C1-INH reported family members who died from an HAE attack. Another cohort found no increased risk of death (odds ratio 0.69; 95% CI, 0.38 to 1.26) among HAE patients. The sponsor's annual report states a 30% risk of asphyxiation if an attack with airway obstruction remains untreated and, citing scientific publications, that patients experience a median of 14 attacks per year.

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/); [Bork et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16490473/); [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Bork et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12767961/); [Zanichelli et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26304015/); [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z); [Bork et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22841766/); [Minafra et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35526778/); [Minafra et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34687444/); [Christiansen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37619776/); [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-1.1.1-3"></a>

##### Summary: humanistic and economic burden

In a survey of 457 respondents, SF-12 Physical and Mental Component Summary scores were lower than population norms (mean 43.7 versus 49.6 and 42.6 versus 49.4; p < 0.001 for each), 42.5% had depression scores above 8.5, “indicative of depressive symptomatology”, overall work impairment was 34%, and workers lost a mean of 3.3 days because of their most recent attack. In a survey of 260 participants, respondents reported a mean of 11.5 attacks (SD 14.2) in the past 6 months, 137 of 260 (52.7%) had an AE-QoL total score of 39 or higher, and 69 (26.5%) and 27 (10.4%) had moderate to severe anxiety and depression by HADS; a survey of 242 participants in Australia, Austria, Canada, France, Germany, Spain, Switzerland, and the United Kingdom reported moderate to severe anxiety and depression in 38.0% and 17.4%. Among 100 US adults receiving long-term prophylaxis and/or on-demand therapies, 80% reported at least 1 attack in the past year. The prevalence of presumptive post-traumatic stress disorder was between 20 and 25% among 77 participants with HAE due to C1-INH deficiency. In a US survey, the mean EQ-5D-5L index score in the treated cohort (94 respondents) was 0.849 “Today” and 0.568 “During the last treated attack”, and a European survey mapped to EQ-5D reported mean utilities of 0.44 during an attack and 0.72 between attacks.

In claims for 328 patients, mean annualized total HAE-related healthcare costs per patient were $165,348 before and $515,333 after starting long-term prophylaxis, driven by prophylaxis pharmacy costs (mean $395,845 per patient per year). Modeled on-demand-only treatment carried direct costs of $363,795 and indirect socioeconomic costs of $52,576 per patient per year, with medications accounting for 62.5% ($227,674). Another analysis reported annualized expenditures for on-demand prescriptions, hospitalizations, and emergency department visits averaging more than $200,000 even after initiation of subcutaneous prophylaxis. In 2006 and 2007, there were 5040 emergency department visits with HAE, of which 2059 (40.9%) resulted in a hospitalization, and mean HAE emergency department visit costs were $1479 (95% confidence interval, $1028 to 1929). In a cohort at a Milan center, the average cost per attack was €1183 (SD €789), or €11 912 per patient per year. A European patient survey estimated 20 days missed from work or school per year on average, and 51% of respondents indicated that HAE had hindered their career or educational advancement; a review reported an income loss of $3402 annually from work missed because of acute attacks.

Source: [Lumry et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20929608/); [Watt et al. (2026b)](https://link.springer.com/article/10.1186/s13023-025-04134-z); [Mendivil et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7893968/); [Busse et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41698689/); [Christiansen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13488251/); [O'Connor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12320545/); [Aygören-Pürsün et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5019462/); [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/); [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/); [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/); [Zilberberg et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22195693/); [Federici et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6067408/); [Aygören-Pürsün et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4105891/); [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)

<a id="topic-1.1.1-4"></a>

##### Summary: caregiver burden

In an international survey of 120 caregivers, sponsored by Takeda Development Center Americas, Inc., caregivers of pediatric patients reported being absent from work for a mean of 2.6 days (SD 5.8) in the preceding 4 weeks, while the children in their care missed a mean of 3.9 days (SD 6.2) of school; caregivers reported providing care for a mean of 23.5 days (SD 11.8) per month, 33.3% of caregivers of pediatric patients reported that caregiving limited their ability to work full time, and help provided by caregivers during the patient's most recent attack included administering HAE medication (51.5%). In a European patient survey, patients reported that their caregivers missed 3.3, 3.6, and 10.1 days among patients with attacks less than once a month, at least once a month but less than once a week, and at least once a week, respectively (p = 0.088). In interviews in the US and UK, six patients (43%) using icatibant required a parent or caregiver to administer it, including two of the 10 adult patients (20%) and all adolescents (n = 2). In a time trade-off valuation by members of the general public in England, the caregiver health state was rated 0.762 (SD 0.303).

Source: [Watt et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12895942/); [Aygören-Pürsün et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4105891/); [Yong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12715920/); [Lo et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8864034/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Deucrictibant Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary: RAPIDe-3 phase 3 design and analysis sets

- RAPIDe-3 compared oral deucrictibant immediate-release capsule 20 mg with placebo in a randomised, double-blind, two-period, two-sequence (2 × 2) crossover design. Participants were randomly allocated 1:1 to a deucrictibant-placebo or placebo-deucrictibant sequence to treat two qualifying attacks, stratified by age (≥12 to <18 years or ≥18 years) and by concomitant long-term prophylaxis use at screening. A washout of at least 72 h was required before the next attack was treated with study drug.
- Adolescents aged ≥12 to <18 years and adults aged ≥18 to ≤75 years with hereditary angioedema, including normal C1 inhibitor with a documented genetic variant, were eligible if they had at least two attacks in the 3 months before screening and experience effectively using conventional on-demand therapy; participants using long-term prophylaxis were also eligible.
- Qualifying attacks were non-laryngeal attacks with at least one AMRA symptom item score of 20 or more, or non-severe laryngeal attacks without breathing difficulties or stridor. Adults with severe laryngeal attacks and adolescents with laryngeal attacks of any severity were instructed to take conventional on-demand therapy instead of study drug.
- The sample size calculation assumed median times to onset of symptom relief of 2 h with deucrictibant and 5 h with placebo; 60 participants in the primary efficacy analysis set would provide at least 90% power, and approximately 120 participants were planned for enrollment.
- Between April 4, 2024, and Sept 1, 2025, 134 participants (ten [7%] adolescents and 124 [93%] adults) were enrolled and randomly allocated at 59 sites across 24 countries in the publication, and the registry record lists 76 locations. 113 participants treated 201 attacks, and the primary efficacy analysis set comprised 88 participants who treated one attack with each study drug (176 attacks). The sponsor ended the trial once the prespecified number of participants with paired treated attacks was reached, before all participants had treated two attacks.
- Of the 134 participants, 58 (43%) were male and the median age was 38.0 years (IQR 27.0 to 50.0); four (3%) had hereditary angioedema with normal C1 inhibitor. Of the 113 participants who treated at least one attack, 26 (23%) were receiving long-term prophylaxis.
- Primary analyses used the primary efficacy analysis set; sensitivity and subgroup analyses used all participants with at least one treated attack; safety analyses included all participants who received at least one dose, were based on actual treatment, and were descriptive. Use of rescue or selected prohibited medication was counted as treatment failure, and a gatekeeping procedure controlled the type 1 error rate at a two-sided alpha of 0.05 across the primary endpoint and the secondary endpoints in a fixed order.

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext); [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-1.1.2-2"></a>

##### Summary: RAPIDe-3 primary and key secondary endpoints

In the primary efficacy analysis set of 88 participants with paired attacks (post-treatment data for 83 deucrictibant-treated and 87 placebo-treated attacks for most endpoints), results for deucrictibant and placebo, respectively, were:

- Primary endpoint, time to onset of symptom relief (PGI-C rating of at least a little better for two consecutive timepoints within 12 h): median 1.28 h (95% CI 1.05 to 1.52) and more than 12 h (5.82 to >12); p<0.0001.
- Onset of symptom relief at 4 h: 69 (83%) of 83 and 24 (28%) of 87 attacks; p<0.0001.
- Time to substantial symptom relief (PGI-C): median 2.85 h (2.08 to 3.35) and more than 12 h (10.30 to >12).
- Time to reduction in attack severity (PGI-S): median 2.41 h (1.70 to 2.98) and more than 12 h (12.34 to >12).
- Time to complete symptom resolution (PGI-S rating of none within 48 h): median 11.95 h (8.61 to 21.79) and more than 48 h (>48 to >48).
- Time to end of progression (PGI-C): median 17.47 min (16.27 to 19.17) and 228.67 min (61.82 to 599.60).
- Complete symptom resolution with one dose at 24 h (PGI-S): 50 (60%) of 83 and 13 (15%) of 88 attacks.
- Endpoints assessed with AMRA: median 3.37 h and more than 12 h to substantial symptom relief, 6.94 h and more than 24 h to almost complete or complete symptom resolution, and 25.25 min and 272.09 min to end of progression.
- p<0.0001 for each secondary endpoint listed above. The primary endpoint and the secondary endpoints were reached within their prespecified timeframes by 82% to 93% of deucrictibant-treated attacks and 37% to 61% of placebo-treated attacks.
- Prespecified sensitivity analyses in the 113 participants with at least one treated attack, and supplementary analyses of the primary endpoint in the per-protocol set and with a treatment policy strategy, were reported as consistent with the primary analyses.

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-1.1.2-3"></a>

##### Summary: RAPIDe-3 second capsule and rescue medication use

- In the primary analysis of 88 paired attacks, 73 (83%) and 69 (78%) of 88 deucrictibant-treated attacks and 29 (33%) and 27 (31%) of 88 placebo-treated attacks were treated with a single capsule within 12 h and 24 h, respectively.
- A second capsule was used for 15 (17%) and 19 (22%) of 88 deucrictibant-treated attacks and 59 (67%) and 61 (69%) of 88 placebo-treated attacks within 12 h and 24 h, respectively. A second capsule was permitted 4 h or later after the first, and for laryngeal attacks it was not permitted.
- Conventional on-demand therapy was used as rescue medication within 12 h for six (7%) of 88 deucrictibant-treated attacks and 32 (36%) of 88 placebo-treated attacks, and within 24 h for eight (9%) and 39 (44%), respectively (p<0.0001).
- Of the 77 deucrictibant-treated attacks that reached end of progression within 12 hours, 75 (97.4%) were treated with a single capsule, and more than 95% of deucrictibant-treated attacks maintained the predefined endpoints throughout their assessment periods.

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext); [Anderson et al. (2026c)](https://ir.pharvaris.com/static-files/9d17729a-c3ad-4b4b-a355-40e360776318)

<a id="topic-1.1.2-4"></a>

##### Summary: RAPIDe-3 adolescents and subgroups

- Ten adolescents (7%) were enrolled, and 5 (5.7%) of the 88 participants in the primary efficacy analysis set were aged ≥12 to <18 years. Adolescents had a body weight requirement of ≥40 kg.
- Before randomisation, the ten adolescents each received one deucrictibant capsule in a non-attack state. Mean plasma levels reached the EC85 of 13.8 ng/mL within 15 min and were maintained to at least the last measured time point of 8 h. Three (30%) of the ten adolescents reported treatment-emergent adverse events (four events) after this dose, none related to study drug.
- In participants with at least one treated attack, outcomes were reported as consistent across subgroups defined by age, hereditary angioedema type, use of long-term prophylaxis, and attack location and severity.
- In the two participants with hereditary angioedema with normal C1 inhibitor, each with one deucrictibant-treated attack, time to onset of symptom relief was 1.53 h and 0.84 h; the authors stated that “the small dataset and absence of placebo control prevent further speculation on these findings”.
- Median time to onset of symptom relief with deucrictibant and placebo was 1.20 h and 6.55 h in the North America subgroup (38 participants) and 1.28 h and more than 12 h in the Europe and rest of world subgroup (96 participants).

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext); [Anderson et al. (2026c)](https://ir.pharvaris.com/static-files/9d17729a-c3ad-4b4b-a355-40e360776318); [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779); [Adatia et al. (2026)](https://ir.pharvaris.com/static-files/9ecee56b-8c9c-475e-8f67-04661081af79)

<a id="topic-1.1.2-5"></a>

##### Summary: RAPIDe-3 safety

- In the safety analysis set, 24 (24%) of 100 participants receiving deucrictibant and 17 (17%) of 101 receiving placebo reported treatment-emergent adverse events; within 3 days of treatment, the window the authors considered temporally clinically relevant, the figures were 15 (15%) and two (2%), and all events within 3 days were mild or moderate.
- Six treatment-related events in five (5%) deucrictibant-treated participants (one event each of dyspepsia, fatigue, lethargy, brain fog, headache, and somnolence) resolved within 24 h; one related event of pruritus occurred with placebo.
- One (1%) participant in each group had a serious adverse event: a laryngeal attack requiring hospital admission 132 days after deucrictibant, and a spontaneous miscarriage 45 days after placebo. None of the serious or severe events were considered related to study drug.
- No treatment-emergent adverse events led to treatment discontinuation or death, and none were associated with changes in clinical laboratory, vital sign, or electrocardiogram parameters. No difficulty swallowing the capsule was reported, including for laryngeal attacks, and no vomiting after study drug was reported in participants with abdominal symptoms.

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-1.1.2-6"></a>

##### Summary: RAPIDe-1 phase 2 dose-ranging results and safety

- RAPIDe-1 was a double-blind, randomised, placebo-controlled, crossover, dose-ranging, 2-part phase 2 trial in adults aged 18 to 75 years with hereditary angioedema type 1 or 2. Participants were randomly assigned 1:1:1 to deucrictibant 10 mg, 20 mg, or 30 mg and to one of three sequences treating three attacks (two with deucrictibant and one with placebo). Patients receiving long-term prophylaxis at screening were not eligible, and attacks involving the internal head or neck, including laryngeal attacks, or presenting with vomiting did not qualify.
- 74 participants were randomly assigned; the primary efficacy analysis included 147 attacks in 62 participants, of whom 42 (68%) were female and 60 (97%) were White.
- Primary endpoint, change in VAS-3 score from pre-treatment to 4 h: least squares mean difference versus placebo of −15.02 (95% CI −20.22 to −9.81) for 20 mg and −16.28 (−21.27 to −11.29) for 30 mg (p<0.0001 for both), and −16.75 (−21.52 to −11.97) for 10 mg, which was analysed descriptively without multiplicity control. All hypotheses in the 20 mg and 30 mg testing branches were rejected at the allocated α of 0.025.
- Median time to onset of symptom relief (≥30% reduction in VAS-3) was 2.1 h, 2.7 h, and 2.5 h with 10 mg, 20 mg, and 30 mg, and 8.0 h with placebo.
- Almost complete or complete symptom resolution within 24 h without rescue medication occurred in 71% (20 of 28) of attacks with 20 mg, 74% (23 of 31) with 30 mg, and 16% (eight of 51) with placebo. Rescue medication was used within 24 h for 9 (24%), 3 (11%), and 4 (13%) attacks with 10 mg, 20 mg, and 30 mg and 37 (73%) with placebo; median time to first rescue medication use was 6.0 h after placebo and non-evaluable after deucrictibant.
- In a post-hoc analysis of the same 147 attacks, median time to end of progression was 25 to 26 minutes with deucrictibant and 20 hours with placebo.
- Safety: in Part 1, eight (11%) of 72 participants in the safety analysis set reported treatment-emergent adverse events within 5 days, two of them mild treatment-related events (nausea and headache). In Part 2 (156 attacks), three moderate treatment-related events (nausea, vomiting, and fatigue) occurred in one participant about 20 h after a 30 mg dose, and one treatment-related blister occurred after placebo. No severe, serious, or discontinuation-related treatment-emergent adverse events were reported.

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext); [Riedl et al. (2023c)](https://ir.pharvaris.com/static-files/0bae214b-7ff8-49ec-8340-1bb60a5935b9)

<a id="topic-1.1.2-7"></a>

##### Summary: RAPIDe-2 long-term open-label extension results and safety

- RAPIDe-2 is a single-group phase 2/3 extension with no masking in its registry record. In Part A, adults who completed RAPIDe-1 remained blinded to their dose (10 mg, 20 mg, or 30 mg), treated every attack with active drug, could treat upper airway attacks including laryngeal attacks, and could not use long-term prophylaxis. Part B is open-label and includes participants aged 12 years and older rolling over from RAPIDe-3, and the registry admits participants on a stable long-term prophylaxis regimen. The primary endpoint is safety, analysed descriptively.
- Part A results, reported for the combined dose group, included 465 attacks treated by 19 participants. Median times were 1.1 h (95% CI 1.0 to 1.1) to onset of symptom relief, 2.5 h to substantial symptom relief, 2.8 h to reduction in attack severity, and 10.6 h to complete attack resolution.
- Onset of symptom relief by 12 hours was reached in 97.8% (447/457) of attacks and complete symptom resolution at 24 hours in 86.9% (390/449). A single dose was used for 86.2% (394/457) of attacks with post-treatment PGI-C data in one report and for 84.9% (395/465) of all treated attacks in another. Eight attacks used rescue medication within 24 hours.
- Among attacks that reached each milestone with a single dose, 98.3% (344/350) maintained onset of symptom relief and 99.2% (382/385) maintained complete attack resolution without symptom reoccurrence.
- Upper airway attacks: 14 upper airway attacks, including laryngeal attacks, were treated by seven participants, and difficulty swallowing or voice change was reported before treatment in six attacks. Median time to onset of symptom relief was 1.4 h (0.8 to 3.0) and to complete attack resolution 8.9 h (3.9 to 36.3), compared with 1.1 h and 10.6 h for all 451 non-upper airway attacks. One participant used rescue medication for one upper airway attack.
- Safety in Part A: 12 (2.6%) attacks had a treatment-emergent adverse event, with no treatment-related events. One serious event (tooth caries) was unrelated to treatment, and no events led to discontinuation, withdrawal, or death. In the ongoing Part B, 1 (0.9%) of 110 participants had a treatment-related tachycardia event and none had treatment-related vascular disorder events.

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105); [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54); [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c); [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029); [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-1.1.2-8"></a>

##### Summary: phase 1 pharmacology and integrated safety

- In PHA121-C001, 52 healthy participants received single ascending oral doses of an oral solution up to 22 mg and 16 received placebo. 17 adverse events were reported by 12 of 52 participants on study drug and 7 by 5 of 16 on placebo; none were serious or severe, and treatment-related events in three participants receiving 12 or 22 mg were mild gastrointestinal events. Across two single ascending dose studies (1 to 50 mg), adverse events occurred in 25% of participants on deucrictibant and 25% on placebo, with no dose-related increase.
- Peak plasma levels were reached within 30 to 60 minutes under fasted conditions, exposure was dose proportional, and mean half-life ranged from 3.5 to 5.6 h between doses. In a bradykinin challenge in 16 healthy volunteers, the average composite EC50 and EC85 were 2.4 and 13.8 ng/mL, and doses of 12 and 22 mg provided bradykinin antagonism for longer than a 30 mg subcutaneous icatibant injection.
- After a single 20 mg immediate-release capsule, mean plasma levels reached the EC85 within 15 to 30 min and were maintained for 8 h or longer; mean elimination half-life is approximately 5.1 h.
- As of June 10, 2026, an estimated 743 unique participants had been exposed to deucrictibant across 25 company-sponsored studies (339 healthy participants, 16 with hepatic impairment, 24 with renal impairment, and approximately 312 with hereditary angioedema).
- No treatment-related cardiac or vascular disorder adverse events occurred across the phase 1 single-dose studies, RAPIDe-1, the randomised part of CHAPTER-1 (twice-daily immediate-release capsules), RAPIDe-2 Part A, or RAPIDe-3. In phase 1 multiple-dose studies, 1 (0.4%) of 232 healthy participants had treatment-related orthostatic hypotension.
- A concentration-QTcF analysis of pooled phase 1 studies estimated a ΔΔQTcF of −2.55 ms (upper 90% CI +2.29 ms) at the highest estimated clinical exposure, below the 10 ms regulatory threshold, and the FDA accepted thorough QT study waiver requests for the immediate-release and extended-release formulations.
- In August 2022 the FDA placed a clinical hold on US trials based on repeat-dose rat findings; after review of an interim analysis of a 26-week rodent toxicology study, the hold on the on-demand application was lifted in June 2023.
- Pregnant and breastfeeding women were not eligible for RAPIDe-1 or RAPIDe-3, and both trials excluded participants with abnormal hepatic function and with abnormal renal function. Single-dose pharmacokinetic studies in hepatic impairment and in renal impairment are listed by the company.

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm); [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b); [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b); [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31); [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext); [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853); [Pharvaris Form 6-K, first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_1.htm); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext); [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-1.1.2-9"></a>

##### Summary: differences between reporting documents

The documents report the following figures differently; each is given with its source.

- RAPIDe-3 median time to end of progression: 17.47 min in the Lancet publication and 17.48 minutes in the NDA acceptance release.
- RAPIDe-3 placebo median time to complete symptom resolution: more than 24 hours in the December 2025 topline release, and more than 48 h in the Lancet publication and the Form 20-F.
- RAPIDe-3 dates and sites: registry study start 2024-02-26 with 76 locations; screening from April 4, 2024, at 59 sites across 24 countries in the Lancet publication; trial initiation in March 2024 in the Form 20-F.
- RAPIDe-3 group sizes: the Lancet safety table counts 100 participants receiving deucrictibant and 101 receiving placebo, while its attack counts are 101 deucrictibant-treated and 100 placebo-treated attacks. The topline presentation states that one participant randomized to the deucrictibant-placebo sequence was incorrectly given placebo for the first attack.
- RAPIDe-1 sites: 38 in the Lancet Haematology publication, 36 locations in the registry, 33 sites (13 countries) in the topline release, and about 30 sites in a March 2023 presentation.
- RAPIDe-1 10 mg results: the publication reports no p value for 10 mg and analysed it descriptively, while the registry gives a nominal p value of <0.0001 for the primary endpoint and the topline release gives p values for 10 mg rescue medication use.
- RAPIDe-1 safety analysis set: 72 participants in Part 1 in the publication, and 156 attacks from 73 participants in a March 2023 presentation.
- RAPIDe-2 planned enrollment: 150 in ClinicalTrials.gov and 72 in the EU Clinical Trials Register. Study code: PHA022121-C303 in the registry and C201 in a Form 20-F heading.
- RAPIDe-2 single-dose proportion: 86.2% (394/457 attacks with post-treatment PGI-C data) and 84.9% (395/465 treated attacks).
- Half-life: 3.5 to 5.6 h after single ascending doses of oral solution, 4.8 to 7.3 h after multiple dosing, 5.10 h after a 2 x 20 mg immediate-release capsule dose, and approximately 5.1 h in the Lancet publication.
- Food effect at 22 mg: AUClast 49% higher with a high-calorie, high-fat breakfast in one report, and AUCinf 42% higher in another report and the registration statement, the 42% figure attributed to a result “mainly caused by one outlier”.
- Duration above the EC85: approximately 12 h after 12 and 22 mg oral solution and after a 2 x 10 mg immediate-release capsule dose; 8 h or longer after the immediate-release capsule in RAPIDe-1; approximately 8 hours at 10 or 20 mg and more than 10 hours at 30 mg in a RAPIDe-1 poster.
- CYP3A4 exclusion: moderate or potent inhibitors or inducers in RAPIDe-1, and strong inhibitors or inducers in RAPIDe-3 and the RAPIDe-2 registry record.

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext); [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application); [Pharvaris RAPIDe-3 topline press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525305951/d69798dex991.htm); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779); [Pharvaris RAPIDe-3 topline data presentation (2025)](https://ir.pharvaris.com/static-files/30661839-e400-44eb-a1e9-9ad88f75d404); [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext); [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211); [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211); [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm); [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e); [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105); [EU Clinical Trials Register 2021-006906-58](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-006906-58/ES); [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54); [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c); [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b); [Groen et al. (2021)](https://ir.pharvaris.com/static-files/f7f8b87d-c488-4611-b3a6-a2275aa94143); [Zhang et al. (2025)](https://ir.pharvaris.com/static-files/1680a98e-6898-4ee8-afb4-12d1ff5eb47a); [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b); [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm); [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f); [Maurer et al. (2023a)](https://ir.pharvaris.com/static-files/351671e4-35b8-4bc3-a50d-ef96e17059ab)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Deucrictibant

<a id="topic-1.1.3-1"></a>

##### Summary

Pharvaris states in its 2026 Form 20-F that it does not have any drugs that have received regulatory approval, and in its third quarter 2026 discussion that it expects to recognize revenues from sales in 2027 if deucrictibant IR is approved for sale by the FDA. No wholesale acquisition cost, list price, or budget impact model for deucrictibant was identified. The company expects that its product candidates, if approved, will be priced at a “significant premium over competitive generic products”, and states that generic products expected over the coming years may create pricing pressure. Its third quarter 2026 expenses include build-out of a commercial organization, pricing research, and HAE market data supporting a potential launch of IR in 2027.

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [Pharvaris Form 6-K, third quarter 2026 MD&A (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm)

<a id="topic-1.1.3-2"></a>

##### Summary: acquisition prices of on-demand comparators

- Oral sebetralstat (Ekterly): wholesale acquisition cost (WAC) at introduction on 2025-07-07 of $33,440.0000 for a pack of 4 tablets of 300 mg (California filing); the Missouri Medicaid fact blast states $8,360 per tablet, $16,720 per dose of two 300-mg tablets, and $33,440 per package of two doses. KalVista's 2026 Colorado disclosure states a WAC of $35,614 per carton of 4 tablets, and a California filing records a WAC at introduction of $35,614.0000 for a 4-tablet pack introduced 2026-09-21.
- Berinert 500 units: WAC of $4,442.47 effective 01/01/2026, up from $3,250.00 on 01/01/2021.
- Ruconest 2100 U, 1 carton: WAC of $8,075.00 effective 01/01/2025.
- Icatibant: the Sajazir manufacturer states that the WAC for Firazyr was $11,147.49 at its 2021 introduction. Generic icatibant WACs at introduction include $5,083.26 per single syringe (Teva, 2019-07-15), $1,000.00 per single syringe (AuroMedics, 2025-05-20), and $750.00 per single vial (Alembic, 2025-09-25).
- Federal Supply Schedule (FSS) and Big Four prices in the 2026 VA file: Firazyr 30 mg/3 mL, $9,522.98 FSS and $7,284.86 Big Four per syringe; generic icatibant, $979.90 FSS (NDC 63323-0574-86) and $2,317.97 FSS (NDC 00093-3066-34) per 3 mL syringe; Kalbitor 3 x 1 mL, $16,754.10 FSS and $12,431.63 Big Four; Berinert 500 IU vial, $3,217.25 FSS and $2,650.06 Big Four; Ruconest 2100 unit vial, $4,918.75 FSS and Big Four.
- Medicare Part B payment limits effective October 1 to December 31, 2026, based on 2Q26 ASP data: Berinert $79.329 per 10 units, Ruconest $37.810 per 10 units, and Kalbitor $599.616 per 1 mg.

Source: [California HCAI prescription drugs introduced to market (2025)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/80eea566-e1a0-4b62-884b-b0dfb58887e3/download/q1-q4-2025-prescription-drugs-introduced-to-market.xlsx); [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx); [KalVista Pharmaceuticals Colorado WAC disclosure (2026)](https://www.kalvista.com/wp-content/uploads/2026/05/Colorado-WAC-Disclosure-Ekterly-updated-20260504.pdf); [California HCAI prescription drugs introduced to market (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv); [California HCAI five-year WAC increase history (2026)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/d754c567-c3c3-4ecf-a236-8144578549dd/download/5-year-wac-increase-history-jan-oct-2026.csv); [California HCAI WAC increase data (2025)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/46b78eef-5952-4fff-84c7-1fa758990ce8/download/q1-q4-2025-prescription-drug-wac-increases.xlsx); [California HCAI prescription drugs introduced to market (2021)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/5a80b890-24bb-4d66-a0bb-d6c46a150065/download/q1-q4-2021-prescription-drugs-introduced-to-market.xlsx); [California HCAI prescription drugs introduced to market (2019)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/6393cda0-6101-424e-b738-07aee9e6f94f/download/q1-q4-2019-prescription-drugs-introduced-to-market.xlsx); [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://department.va.gov/procurement-acquisition-and-logistics/wp-content/uploads/sites/56/2026/11/TPharmPrices-11-01-2026.xlsx); [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

<a id="topic-1.1.3-3"></a>

##### Summary: cost per attack, redosing, and annual costs

- Cost per attack: the 2018 ICER report states that on-demand medications range in cost from $5,000 to more than $12,000 per attack treated in the US. A US commercial payer decision model, with costs dated to 2019, estimated costs per attack of $12,905 for rhC1-INH, $14,806 for icatibant, $14,668 for pdC1-INH, and $21,068 for ecallantide. In an Italian cohort (Italian National Health Service perspective), the average cost per attack was €1183 (SD €789), €1069 with pdC1-INH and €1651 with icatibant (unadjusted).
- Redosing: the Missouri Medicaid fact blast reports redosing in 13% to 38% of episodes with sebetralstat, 7% to 44% with icatibant, 8% to 30% with Berinert, 6% to 18% with Kalbitor, and 2% to 10% with Ruconest. The NICE draft guidance records additional dosing rates of 22.25% for sebetralstat (KONFIDENT-S), 8.91% for icatibant, 18.18% for Cinryze and Ruconest, and 1.11% for Berinert. Cigna states that the second rescue dose was given for 39.8% of Ekterly-treated attacks. The ICER model used extra-dose percentages of 1.9% (Berinert), 12.0% (Kalbitor), 12.7% (Firazyr), and 6.6% (Ruconest).
- Annual costs: modeled on-demand-only treatment in a patient survey carried direct costs of $363,795 and indirect costs of $52,576 per patient per year, with medications at $227,674 (62.5%). In claims data for 328 patients, mean annualized HAE-related healthcare costs were $165,348 before and $515,333 after starting long-term prophylaxis, and 67% had at least 1 post-index on-demand therapy claim; on-demand pharmacy costs among patients with at least 1 claim were $217,857 pre-index and $167,462 post-index per patient per year. In an analysis of a commercial claims database across the United States, on-demand therapy spend in 29 on-demand-experienced members declined by an average of $47,358 per member after starting long-term prophylaxis, with allowed cost per member of $108,748 before and $61,390 after (-43.6%). Kutrieb et al. (2026) report annualized expenditures for on-demand prescriptions, hospitalizations, and ED visits averaging more than $200,000 even after initiation of subcutaneous long-term prophylaxis.
- Acute care unit costs: mean HAE ED visit costs were $1479 (95% confidence interval, $1028-1929) in the 2006-2007 Nationwide Emergency Department Sample.

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf); [Bernstein et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391298/); [Federici et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6067408/); [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx); [NICE sebetralstat draft guidance (2025)](https://www.nice.org.uk/guidance/gid-ta11334/documents/draft-guidance); [Cigna Ekterly drug quantity management policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_934_coveragepositioncriteria_hae_ekterly_dqm_per_days.pdf); [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/); [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/); [Heuring et al. (2026)](https://www.primetherapeutics.com/documents/d/primetherapeutics/EVT_EXT_670100-H_AMCPPstr_RealWorldPatternsOfOnDemandUtilization_R4-2_Web); [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/); [Zilberberg et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22195693/)

<a id="topic-1.1.3-4"></a>

##### Summary: payer utilization management of on-demand agents

- Cigna (review date 07/08/2026) sets Ekterly quantity limits sufficient to treat 4 attacks at the maximum dose per 28 days, with an override for an additional 4 attacks each month.
- Univera Healthcare requires, for patients 18 years and older, documentation of therapeutic failure, severe intolerance, or a contraindication to generic icatibant before Ekterly, with a quantity limit of 4 tablets per 30 days; brand Firazyr also requires documentation regarding a trial of generic icatibant, and only one acute HAE medication is authorized at one time.
- Regence (effective April 1, 2026) requires documentation that generic icatibant and at least one of Berinert or Ruconest have been ineffective, not tolerated, or contraindicated, authorizes acute treatments in a quantity sufficient for three attacks per month, and states that generic icatibant is the lowest cost of all available options.
- CountyCare's medical benefit guideline covers Berinert (J0597), Firazyr (J1744), Kalbitor (J1290), and Ruconest (J0596), and requires trial and failure or intolerance of the preferred product for non-preferred requests.
- MO HealthNet prior authorization for Ekterly requires use for on-demand treatment of acute HAE attacks, with an initial approval period of 6 months; its fact blast lists deucrictibant with a phase III trial (NCT06669754) and an estimated completion of August 2026; the sponsor identifies NCT06669754 as CHAPTER-3, its trial of deucrictibant XR for prophylaxis.

Source: [Cigna Ekterly drug quantity management policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_934_coveragepositioncriteria_hae_ekterly_dqm_per_days.pdf); [Univera Healthcare hereditary angioedema pharmacy policy (2026)](https://www.univerahealthcare.com/documents/d/global/hereditary-angioedema-hae-pdf); [Regence medication policy dru535 (2026)](https://regence.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/Cambia/Program_Summaries/dru535reg.pdf); [CountyCare acute HAE products guideline (2026)](https://countycare.com/wp-content/uploads/ECG_5000.CC-for-Acute-Hereditary-Angioedema-Products-ver-Jan-26.pdf); [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx); [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-1.1.3-5"></a>

##### Summary: population and payer mix

- US diagnosed population: a claims-based algorithm estimated 9559, 9341, and 8694 people diagnosed with HAE in 2018, 2019, and 2020 (2.67, 2.61, and 2.43 per 100,000), and expert physician analysis estimated 7602, 7275, and 6595. Castaldo et al. (2021) state that HAE due to C1 inhibitor deficiency affects fewer than 8000 people in the United States. The Pharvaris 20-F cites HAE International, as of October 2014, for at least 7,000 patients in the U.S. and at least 15,000 in the EU.
- Treatment pattern: of 737 survey respondents, 37.3% (n = 275) were prescribed and using on-demand-only treatment. Tachdjian et al. (2026) state that approximately 70% of US patients with HAE are treated with long-term prophylaxis.
- Payer mix: The California filing for sebetralstat states marketing investments organized to reflect a payer mix of 70% commercial payors, 25% Medicare Part D, and 5% Medicaid, with an estimated 780 patients in the 2025 filing and 7500 in the 2026 filing.
- Medicare Part D spending in 2024 was $43713828.6 for Firazyr (170 beneficiaries), $32477428.42 for generic icatibant (658 beneficiaries), $34597556.94 for Berinert (63 beneficiaries), $55710878.24 for Ruconest (128 beneficiaries), and $20871584.35 for Kalbitor (36 beneficiaries).

Source: [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/); [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/); [California HCAI prescription drugs introduced to market (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv); [California HCAI prescription drugs introduced to market (2025)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/80eea566-e1a0-4b62-884b-b0dfb58887e3/download/q1-q4-2025-prescription-drugs-introduced-to-market.xlsx); [CMS Medicare Part D Spending by Drug (2026)](https://data.cms.gov/sites/default/files/2026-06/98218f98-166c-4723-8438-c344a4ef96a6/DSD_PTD_RY26_P04_V10_DY24_BGM.csv)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

- Disease burden and unmet need: hereditary angioedema is estimated to affect 1 in 50,000 people worldwide, and a US claims-based algorithm estimated 9559, 9341, and 8694 people diagnosed in 2018, 2019, and 2020. Laryngeal involvement occurs at least once in about half of patients, and an analysis of studies including 3292 patients reported 411 deaths from asphyxia due to laryngeal edema. Except for oral sebetralstat, the approved on-demand treatments are given by intravenous or subcutaneous injection. In a survey of 107 respondents, sponsored by KalVista Pharmaceuticals, 57% did not treat all attacks and the mean time to treatment was 2.4 h; in a Pharvaris-supported survey, 84% of patients in the patient-reported group would prefer to take on-demand treatment by mouth.
- Regulatory status: the FDA accepted the New Drug Application for the deucrictibant immediate-release capsule (20 mg) for on-demand treatment of attacks in July 2026, and the European Medicines Agency validated the marketing authorization application in July 2026 and is reviewing it under the centralized procedure. The intended population is adults and adolescents 12 years and older. The company states that it has no drugs with regulatory approval and that FDA approval in 2027 is uncertain. A US expanded access program (NCT07759141) is open to eligible people aged 12 to 75 years.
- Efficacy of the 20 mg capsule: in RAPIDe-3, among 88 participants with one attack treated with each study drug, median time to onset of symptom relief was 1.28 h with deucrictibant and more than 12 h with placebo (p<0.0001), and median time to complete symptom resolution was 11.95 h and more than 48 h. Median time to end of progression was 17.47 min in the Lancet publication and 17.48 minutes in the NDA acceptance release. A single capsule was used within 12 h for 73 (83%) of 88 deucrictibant-treated attacks, and conventional on-demand rescue therapy within 12 h for six (7%) of 88 deucrictibant-treated and 32 (36%) of 88 placebo-treated attacks. In the phase 2 RAPIDe-1 trial, the least squares mean difference versus placebo in VAS-3 score change at 4 h was −15.02 for 20 mg. In Part A of the RAPIDe-2 extension, 19 participants blinded to doses of 10 mg, 20 mg, or 30 mg treated 465 attacks, with a median time to onset of symptom relief of 1.1 hours.
- Safety: in RAPIDe-3, treatment-emergent adverse events were reported by 24 (24%) of 100 participants receiving deucrictibant and 17 (17%) of 101 receiving placebo, and within 3 days by 15 (15%) and two (2%). Six treatment-related events in five deucrictibant-treated participants resolved within 24 h, and no treatment-emergent adverse events led to treatment discontinuation. An estimated 743 participants had been exposed to deucrictibant across 25 company-sponsored studies as of June 10, 2026, and no treatment-related cardiac or vascular disorder events occurred in the phase 1 single-dose studies, RAPIDe-1, RAPIDe-2 Part A, or RAPIDe-3.
- Main limitations of the RAPIDe-3 evidence: attacks were not stratified by location and severity, and severe or very severe attacks at pre-treatment were 17 (17%) of 101 deucrictibant-treated and 29 (29%) of 100 placebo-treated attacks. Severe laryngeal attacks were not included, five adolescents were in the primary efficacy analysis set, and only two unpaired attacks were recorded in participants with hereditary angioedema with normal C1 inhibitor. Eligibility required experience with effectively using conventional on-demand therapies and an age of 75 years or younger, and health-related quality of life outcomes were exploratory endpoints planned for separate publication.
- Relation to current on-demand options: guideline recommendations for first-line on-demand treatment include intravenous C1 inhibitor, icatibant, or sebetralstat, and one guideline states that sebetralstat is the only oral on-demand treatment available. Deucrictibant shares the bradykinin B2 receptor mechanism of icatibant, with a mean elimination half-life of approximately 5.1 h compared with approximately 1.5 h for icatibant. The company describes icatibant, available as a generic product, as the most widely used therapy, and a payer policy states that generic icatibant is the lowest cost of all available options. In the sebetralstat label, the median time to beginning of symptom relief was 2.0 hours with 600 mg, and 38% of patients administered a second dose within 12 hours; the RAPIDe-3 investigators state that variations in trial designs and instruments “prevent direct outcome comparisons”.
- Unknowns: no prescribing information, brand name, wholesale acquisition cost, or budget impact model for deucrictibant was identified; the company expects its product candidates, if approved, to be priced at a “significant premium over competitive generic products”. The company states that it has not conducted a head-to-head comparison of icatibant or any other drug candidate with deucrictibant. Long-term data come from the ongoing RAPIDe-2 study, whose Part A results combine three doses.
- Upcoming milestones: the PDUFA target action date is April 23, 2027, and the European Medicines Agency review is under way. The company expects revenue from sales of the immediate-release capsule in 2027 if the FDA approves it. RAPIDe-2 has an estimated primary completion of 2027-06, and the expanded access program is to continue for up to approximately 6 months after commercial availability.

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/); [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/); [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Minafra et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34687444/); [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf); [Pharming RUCONEST prescribing information (2020)](https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf); [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf); [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf); [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf); [Betschel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12093744/); [Anderson et al. (2026b)](https://link.springer.com/article/10.1007/s12325-026-03790-2); [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application); [Pharvaris Form 6-K, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_1.htm); [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm); [Pharvaris Form 6-K, third quarter 2026 MD&A (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [ClinicalTrials.gov NCT07759141](https://clinicaltrials.gov/study/NCT07759141); [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext); [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext); [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853); [Regence medication policy dru535 (2026)](https://regence.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/Cambia/Program_Summaries/dru535reg.pdf); [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105); [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

## Related pages
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
